PROS AND CONS FOR FLUORESCENT IN SITU
HYBRIDIZATION, KARYOTYPING AND NEXT
GENERATION SEQUENCING FOR DIAGNOSIS AND
FOLLOW-UP OF MULTIPLE MYELOMA
Ikbal Atli E, Gurkan H, Onur Kirkizlar H, Atli E, Demir S, Yalcintepe S, Kalkan R, Demir AM
*Corresponding Author: Assistant Professor Emine Ikbal Atli, Department of Medical Genetics, Faculty
of Medicine, Trakya University, Balkan Campus, Highway D100, Edirne, Turkey 22030. Tel: +284-235-
76-41/23-30. Fax: +284-235-86-52. E-mail: eikbalatli@trakya.edu.tr
page: 59
|
|
REFERENCES
1. Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de
Philippis C, et al. Analysis of the genomic landscape
of multiple myeloma highlights novel prognostic
markers and disease subgroups. Leukemia. 2018;
32(12): 2604-2616.
2. Li S, Lim HH, Woo KS, Kim SH, Han JY. A retrospective
analysis of cytogenetic alterations in patients with
newly diagnosed multiple myeloma: A single center
study in Korea. Blood Res. 2016; 51(2): 122-126.
3. Rajkumar SV. Multiple myeloma: 2014 Update on
diagnosis, risk-stratification, and management. Am
J He-matol. 2014; 89(10): 999-1009.
4. Talley PJ, Chantry AD, Buckle CH. Genetics in myeloma:
Genetic technologies and their application
to screening approaches in myeloma. Br Med Bull.
2015; 113(1): 15-30.
5. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy
J, Palumbo A, Durie B, et al. Consensus recommendations
for risk stratification in multiple myeloma:
Report of the International Myeloma Workshop
Consensus Panel 2. Blood. 2011; 117(18): 4696-4700.
6. Yellapantula V, Hultcrantz M, Rustad EH, Was-serman
E, Londono D, Cimera R, et al. Comprehensive
detection of recurring genomic abnormalities: A targeted
sequencing approach for multiple myeloma.
Blood Cancer J. 2019; 9(12): 101-109.
7. Aydin C, Ulas T, Hangul C, Yucel OK, Iltar U, Salim
O, et al. Conventional cytogenetics and interphase
fluorescence in situ hybridization results in multiple
myeloma: A Turkey laboratory analysis of 381 cases.
Indian J Hematol Blood Transfus. 2020; 36(2): 284-
291. doi: 10. 1007/s12288-019-01215-5. Epub 2019
Oct 25.
8. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel
PL, Chesi M, et al. Genetics and cytogenetics
of multiple myeloma: A workshop report. Cancer Res.
2004; 64(4): 1546-1558.
9. McGowan-Jordan J, Simons A, Schmid M, editors.
An International System for Human Cytogenomic
Nomenclature (ISCN 2016). Basel, Switzerland:
Karger, 2016.
10. Romano A, Palumbo GA, Parrinello NL, Conti-cello
C, Martello M, Terragna C. Minimal residual disease
assessment within the bone marrow of multiple myeloma:
A review of caveats, clinical significance and
future perspectives. Front Oncol. 2019; 9(20): 699.
11. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-
Foster J, et al. Standards and guidelines for the interpretation
of sequence variants: A joint concensus
recommendation of the American College of Medical
Genetics and Genomics and the Association of Molecular
Pathology. Genet Med. 2015; 17(5): 405-424.
doi: 10. 1038/gim. 2015.30.
12. Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz
MA, Stewart AK, et al. Evidence for cytogenetic and
fluorescence in situ hybridization risk stratification of
newly diagnosed multiple myeloma in the era of novel
therapies. Mayo Clin Proc. 2010; 85(6): 532-537.
13. Saxe D, Seo EJ, Bergeron MB, Han JY. Recent advances
in cytogenetic characterization of multiple
myeloma. Int J Lab Hematol. 2019; 41(1): 5-14.
14. Kaufmann H, Ackermann J, Greinix H, Nösslinger T,
Gisslinger H, Keck A, et al. Beneficial effect of highdose
chemotherapy in multiple myeloma patients
with unfavorable prognostic features. Ann Oncol.
2003; 14(11): 1667-1672.
15. Durak BA, Akay OM, Sungar G, Bademci G, Aslan
V, Caferler J, et al. Conventional and molecular cytogenetic
analyses in Turkish patients with multiple
myeloma. Turk J Haematol. 2012; 29(2): 135-142.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
